Literature DB >> 9517922

In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.

D B Hoellman1, S K Spangler, M R Jacobs, P C Appelbaum.   

Abstract

The agar dilution MIC method was used to test the activity of cefminox, a beta-lactamase-stable cephamycin, compared with those of cefoxitin, cefotetan, moxalactam, ceftizoxime, cefotiam, cefamandole, cefoperazone, clindamycin, and metronidazole against 357 anaerobes. Overall, cefminox was the most active beta-lactam, with an MIC at which 50% of isolates are inhibited (MIC50) of 1.0 microg/ml and an MIC90 of 16.0 microg/ml. Other beta-lactams were less active, with respective MIC50s and MIC90s of 2.0 and 64.0 microg/ml for cefoxitin, 2.0 and 128.0 microg/ml for cefotetan, 2.0 and 64.0 microg/ml for moxalactam, 4.0 and > 128.0 microg/ml for ceftizoxime, 16.0 and > 128.0 microg/ml for cefotiam, 8.0 and >128.0 microg/ml for cefamandole, and 4.0 and 128.0 microg/ml for cefoperazone. The clindamycin MIC50 and MIC90 were 0.5 and 8.0 microg/ml, respectively, and the metronidazole MIC50 and MIC90 were 1.0 and 4.0 microg/ml, respectively. Cefminox was especially active against Bacteroides fragilis (MIC90, 2.0 microg/ml), Bacteroides thetaiotaomicron (MIC90, 4.0 microg/ml), fusobacteria (MIC90, 1.0 microg/ml), peptostreptococci (MIC90, 2.0 microg/ml), and clostridia, including Clostridium difficile (MIC90, 2.0 microg/ml). Time-kill studies performed with six representative anaerobic species revealed that at the MIC all compounds except ceftizoxime were bactericidal (99.9% killing) against all strains after 48 h. At 24 h, only cefminox and cefoxitin at 4x the MIC and cefoperazone at 8x the MIC were bactericidal against all strains. After 12 h, at the MIC all compounds except moxalactam, ceftizoxime, cefotiam, cefamandole, clindamycin, and metronidazole gave 90% killing of all strains. After 3 h, cefminox at 2 x the MIC produced the most rapid effect, with 90% killing of all strains.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517922      PMCID: PMC105488     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Pharmacokinetics of cephem antibiotics in exudate of pelvic retroperitoneal space after radical hysterectomy and pelvic lymphadenectomy.

Authors:  K Ito; M Hayasaki; T Tamaya
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

3.  Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology.

Authors:  K E Aldridge; H M Wexler; C V Sanders; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

4.  Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  In-vitro activity of cefotiam against bacteria of clinical interest.

Authors:  B Watt; F V Brown
Journal:  J Antimicrob Chemother       Date:  1982-11       Impact factor: 5.790

6.  Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.

Authors:  P C Appelbaum; M R Jacobs; S K Spangler; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 7.  Mechanisms of beta-lactam resistance in anaerobic bacteria.

Authors:  C E Nord
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

8.  Antibacterial activity of cefminox against anaerobes.

Authors:  K Watanabe; K Sawa; M Bunai; K Ueno
Journal:  J Antibiot (Tokyo)       Date:  1985-05       Impact factor: 2.649

9.  Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

10.  Comparative bactericidal and morphological effects of five cephamycins on cells of three gram-negative bacilli at decreasing drug concentrations.

Authors:  H Goi; T Watanabe; K Miyauchi; Y Kazuno; S Inouye
Journal:  Drugs Exp Clin Res       Date:  1985
View more
  3 in total

1.  Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.

Authors:  Sangeetha Rajenderan; Veeraraghavan Balaji; Shalini Anandan; Rani Diana Sahni; Giannoula S Tansarli; Matthew E Falagas
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

2.  Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.

Authors:  C Betriu; M Gómez; M L Palau; A Sánchez; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

3.  Non-responder phenotype reveals apparent microbiome-wide antibiotic tolerance in the murine gut.

Authors:  Christian Diener; Anna C H Hoge; Sean M Kearney; Ulrike Kusebauch; Sushmita Patwardhan; Robert L Moritz; Susan E Erdman; Sean M Gibbons
Journal:  Commun Biol       Date:  2021-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.